BioSpace News Archive

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically i

Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced its launch and Series A financing of $81 million.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum’s first dual switch GoCAR-T ® product candidate that incorporates the company’s iMC activation and CaspaCIDe ® safety switc

Arbutus Biopharma Corporation today announced additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

The first Mydecine Speaker Series event will feature Mydecine Scientific Advisory Board Members Dr. Robin Carhart-Harris and Dr. Ruth Lanius, Chief Medical Officer Rakesh Jetly and Chief Scientific Officer Robert Roscow

HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda’s discovery portfolio.

Inspyr Therapeutics, Inc., a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces it continues to strengthen its global intellectual property portfolio of adenosine receptor antagonists.

Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in newly diagnosed glioblastoma (GBM) testing the potential survival benefit of initiating Optune concurrent with radiation therapy

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it has received Rare Pediatric Disease (RPD) Designation from the U.S. Food and Drug Administration (FDA) for its lead asset, mavorixafor, for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis

iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and Solis Mammography , the largest independent provider of mammography and breast health services in the United States, today announced a five-year partnership whereby iCAD will provide Solis Mammography’s nationwide network with its latest artificial intelligence (AI)